2.3833
8.33%
-0.2167
Precedente Chiudi:
$2.60
Aprire:
$2.65
Volume 24 ore:
3,768
Relative Volume:
0.22
Capitalizzazione di mercato:
$16.46M
Reddito:
$22.38M
Utile/perdita netta:
$-13.33M
Rapporto P/E:
-0.5261
EPS:
-4.53
Flusso di cassa netto:
$-8.06M
1 W Prestazione:
-16.96%
1M Prestazione:
-16.96%
6M Prestazione:
-62.02%
1 anno Prestazione:
-49.83%
Ezfill Holdings Inc Stock (EZFL) Company Profile
Nome
Ezfill Holdings Inc
Settore
Industria
Telefono
305-791-1169
Indirizzo
67 NW 183RD ST, MIAMI
Confronta EZFL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
EZFL | 2.67 | 16.46M | 22.38M | -13.33M | -8.06M | -4.53 |
CRM | 341.22 | 324.58B | 36.47B | 5.63B | 11.46B | 1.59 |
SAP | 236.29 | 274.15B | 36.09B | 2.98B | 7.67B | 5.2918 |
NOW | 1,049.24 | 215.85B | 10.46B | 1.34B | 3.35B | 7.72 |
INTU | 677.10 | 189.18B | 16.29B | 2.96B | 4.63B | 8.44 |
UBER | 69.53 | 147.99B | 41.96B | 4.40B | 5.96B | -0.22 |
Ezfill Holdings Inc Borsa (EZFL) Ultime notizie
EzFill stock hits 52-week low at $2.19 amid market challenges By Investing.com - Investing.com South Africa
EZFill Holdings Inc. announced that it has received $0.2 million in funding - Marketscreener.com
EzFill stock hits 52-week low at $2.19 amid market challenges - Investing.com
EzFill secures $181.5K loan with NextNRG Holding By Investing.com - Investing.com UK
EzFill Holdings Reports Strong Q3 2024 Growth - TipRanks
EZFLEzFill Holdings, Inc. Latest Stock News & Market Updates - StockTitan
EzFill Announces 2024 Third Quarter Financial Results - GlobeNewswire
EzFill Q3 Revenue Climbs 13%, Delivers Record 1.87M Gallons Amid Strong Growth | EZFL Stock News - StockTitan
Yoshi Mobility Agrees to Sell Its Fleet Fueling Operation to EZFill Holdings - NGT News
Frist's Yoshi Mobility sells fuel division - The Business Journals
EzFill to acquire Yoshi fueling division, eyes national expansion - Investing.com
EzFill Fueling up to Expand Nationally Enters into LOI for the Acquisition of Yoshi Mobility’s Fuel Division - GlobeNewswire
Yoshi Mobility goes green, spins off fueling division - StockTitan
EZFill Holdings Inc. signed a letter of intent to acquire Fueling division of Yoshi, Inc. - Marketscreener.com
EzFill Mobilizes Fleet Actively Supporting Residents and Businesses Impacted By Major Hurricanes Helene and Milton - GlobeNewswire
EzFill Mobilizes Fleet Actively Supporting Residents and Businesses Impacted By Major Hurricanes Helene and - EIN News
EzFill Holdings revises share exchange in NextNRG acquisition - Investing.com
EzFill Holdings revises share exchange in NextNRG acquisition By Investing.com - Investing.com Canada
EZFill Holdings Inc. (NASDAQ:EZFL) Short Interest Down 56.5% in September - Defense World
FDA Approves Miplyffa for Niemann-Pick Disease, Type C - MyChesCo
FDA Approves Miplyffa for Ultra Rare Niemann-Pick Disease Type C - Managed Healthcare Executive
FDA approves Zevra’s Miplyffa for Niemann-Pick disease type C treatment - World Pharmaceutical Frontiers
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 By Investing.com - Investing.com South Africa
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 - Investing.com
Ezzaty Abdullah admits to be delivering her baby soon - Yahoo Lifestyle Singapore
FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease - Pharmaceutical Technology
FDA clears first drug for Niemann-Pick disease - pharmaphorum
Zevra’s Miplyffa wins first FDA approval in Niemann-Pick type C - BioWorld Online
EzFill Holdings (NASDAQ:EZFL) Stock Quotes, Forecast and News Summary - Benzinga
After prior snub, Zevra clinches FDA approval for rare lysosomal storage disorder drug Miplyffa - FiercePharma
First Drug Approved for Niemann-Pick Disease Type C - Medpage Today
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease - Benzinga
Arimoclomol Becomes First FDA Approved Treatment for Neimann-Pick Disease Type C - Pharmacy Times
FDA approves first Niemann-Pick disease, type C treatment - The Pharma Letter
FDA approves arimoclomol as first drug to treat Neimann-Pick disease, type C - Contemporary Pediatrics
EZFill Holdings Inc. (NASDAQ:EZFL) CTO Sells $20,550.00 in Stock - Defense World
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k By Investing.com - Investing.com South Africa
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k - Investing.com India
Extra Storage rises on Jefferies upgrade - XM
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 - Investing.com India
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 By Investing.com - Investing.com Australia
Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article - Morningstar
Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss - MarketWatch
FDA Approves Eli Lilly's Drug for Eczema - Newsmax
Insider Sale: CTO Avishai Vaknin Sells Shares of EzFill Holdings Inc (EZFL) By GuruFocus - Investing.com Canada
EzFill Holdings CTO Avishai Vaknin sells $74,862 in company stock By Investing.com - Investing.com Canada
EzFill Holdings CTO Avishai Vaknin sells $74,862 in company stock - Investing.com
EzFill holdings CTO Avishai Vaknin sells shares worth over $15k - Investing.com
EzFill regains compliance with Nasdaq's equity rule - Investing.com
EzFill Holdings Regains Nasdaq Compliance, Faces Monitoring - TipRanks
EzFill Holdings, Inc. Regains Compliance with NASDAQ Listing Standard - GlobeNewswire
Ezfill Holdings Inc Azioni (EZFL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ezfill Holdings Inc Azioni (EZFL) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Vaknin Avishai | Chief Technology Officer |
Sep 20 '24 |
Sale |
3.45 |
5 |
17 |
65,977 |
Vaknin Avishai | Chief Technology Officer |
Sep 17 '24 |
Sale |
4.20 |
5,061 |
21,244 |
68,933 |
Vaknin Avishai | Chief Technology Officer |
Sep 18 '24 |
Sale |
3.72 |
2,246 |
8,354 |
66,626 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):